Poster

Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain

Abstract: Background: Individuals with major depressive disorder (MDD) with loss of interest and reduced activity respond poorly to serotonergic antidepressants. AXS-05 (dextromethorphan-...

08/20/2024

Latent Variable Analysis of Antipsychotic Adherence among South Carolina Medicaid Beneficiaries with Schizophrenia

Abstract: Schizophrenia, a chronic mental illness, requires long-term treatment with antipsychotics, where adherence is crucial for favorable clinical and economic outcomes. Adherence, ho...

08/20/2024

Experiences and Perceptions of Psychiatrists Treating Schizophrenia With Long-Acting Injectable Antipsychotics: Qualitative Results From the Multinational ADVANCE Study

Abstract: Background: Psychiatrists’ views on schizophrenia treatment goals and use of long-acting injectable antipsychotics (LAIs) vary widely.

08/20/2024

Formation of a working alliance and potential efficacy of a digital therapeutic to treat experiential negative symptoms of schizophrenia

Abstract: Introduction: Currently, no FDA-approved pharmacological treatments satisfactorily address experiential negative symptoms (ENS) of schizophrenia. CT-155 is a prescription digita...

08/20/2024

Comparative Effectiveness of Oral and Long-acting Injectable Antipsychotics in Schizophrenia: A Real-world Study in the US Medicare Population

Abstract: Objective: Long-acting injectables (LAIs) may provide an advantage over daily oral antipsychotics (OAPs), but little real-world evidence exists in the Medicare population, which...

08/20/2024

Content confirmation of the Schizophrenia Cognition Rating Scale (SCoRS): a qualitative study with primary and secondary caregivers

Abstract: Introduction: Cognitive impairments associated with schizophrenia are burdensome and detrimental to everyday life. The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item ...

08/20/2024

Earlier Use of Long-Acting Injectable Paliperidone Palmitate versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis of the PRIDE and PROSIPAL studies

Abstract: Objective: A prior integrated patient-level analysis revealed a significant benefit of implementing paliperidone palmitate (PP) versus oral antipsychotics (OAPs) earlier in the ...

08/20/2024

Effectiveness of Deutetrabenazine for Tardive Dyskinesia When Initiated Using a 4-Week Patient Titration Kit: Final Results of the START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor for the treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)–related c...

08/20/2024

Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomized controlled trial program

Abstract: Rationale No effective pharmacological treatments are available for cognitive impairments in schizophrenia. Iclepertin (BI 425809), a glycine transporter-1 inhibitor, enhances N...

08/20/2024

Enhancing Behavioral Health Workforce: Evaluating the Impact of an HRSA-Funded Interprofessional Training Initiative

Abstract: This research analyzes the outcomes of a federal training grant first awarded in 2017 by the Health Resources and Services Administration (HRSA) to address the shortage of behav...

08/20/2024